{"id":"W4399570650","doi":"10.1200/jco.2024.42.16_suppl.tps9602","title":"A phase 3 trial of IMC-F106C (PRAME x CD3) plus nivolumab versus standard nivolumab regimens in HLA-A*02:01+ patients with previously untreated advanced melanoma (PRISM-MEL-301).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Nivolumab; Medicine; Oncology; Melanoma; Internal medicine; Human leukocyte antigen; Surgery; Immunotherapy; Cancer research; Immunology; Cancer; Antigen","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001516221,0.001830289,0.001582005,0.0004312879,0.0004995379,0.001097442,0.001137707,0.001514181,0.005623795],"category_scores_gemma":[0.0008648871,0.0006420923,0.001540819,0.0003770609,0.001031048,0.001002565,0.000413255,0.005680577,0.001198498],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001227345,"about_ca_system_score_gemma":0.001640713,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001270835,"about_ca_topic_score_gemma":0.003343871,"domain_scores_codex":[0.9995881,0.0001921721,0.00001287313,0.00007778112,0.00004044786,0.00008866996],"domain_scores_gemma":[0.9994082,0.00009768006,0.0001018641,0.00004056786,0.00002885545,0.000322872],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.863535,0.06329118,0.00203565,0.0004960335,0.0007316735,0.0002556016,0.0002709384,0.001885787,0.02369165,0.0003183465,0.003331056,0.04015697],"study_design_scores_gemma":[0.5451431,0.4462833,0.003974263,0.00002635486,0.0002084263,0.0001554534,0.00004710455,0.0009539388,0.001446106,0.0002185496,0.001518335,0.00002507283],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.989985,0.00136813,0.0005261145,0.0007325668,0.0003496011,0.003486869,0.001190418,0.000115543,0.002245816],"genre_scores_gemma":[0.9856758,0.001276973,0.001567279,0.001158968,0.000245237,0.00323801,0.002081569,0.00004020705,0.004715947],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005623795,"threshold_uncertainty_score":0.01881343,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07968899237102706,"score_gpt":0.473497147285629,"score_spread":0.3938081549146019,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}